International Journal of Research in Pharmacy and Pharmaceutical Sciences
www.pharmacyjournal.in
ISSN: 2455-698X
Received: 08-11-2025, Accepted: 07-01-2026, Published: 22-01-2026
Volume 11, Issue 1, 2026, Page No. 60-69

Determinants and consequences of medication adherence in chronic disease management: A mixed-methods investigation

Sarabjit Singh[1], D G Desai[2]
[1] Research scholar, ISBM University, Chattisgarh, India
[2] Professor, ISBM University, Chattisgarh, India

Abstract
This study investigated the relationship between medication adherence and therapeutic outcomes in chronic disease management. A mixed-methods design was employed with a purposive, stratified sample of 250 patients with hypertension, diabetes, asthma, COPD, or cardiovascular disorders from diverse healthcare settings. Adherence was measured using the Morisky Medication Adherence Scale (MMAS-8), pill counts, and pharmacy refills, while outcomes were assessed via clinical parameters (e.g., blood pressure, HbA1c), hospitalization rates, and quality of life scores. The results revealed that only 25% of patients exhibited high adherence, while 30% had low and 45% medium adherence. A strong, dose-response relationship was established: high adherence was significantly associated with superior clinical control (e.g., -3.1 mmHg systolic BP per adherence unit, $p<0.01$), a 3.7-fold greater likelihood of symptom relief ($p<0.01$), and a 27% reduced hospitalization risk ($p<0.01$). Key determinants of adherence were patient-related factors (knowledge, motivation), therapy complexity, side effects, healthcare system support (e.g., follow-ups), and socioeconomic barriers (cost, education). The findings confirm that medication adherence is a pivotal, modifiable predictor of therapeutic success. The study underscores the necessity of implementing multifaceted, patient-centered interventions—including education, regimen simplification, enhanced provider communication, and digital tools—to address the complex determinants of non-adherence, thereby improving clinical outcomes and reducing the healthcare burden of chronic diseases.

Keywords: Morisky medication adherence scale, hypertension, diabetes, asthma, COPD

Introduction

The global rise of chronic diseases, including hypertension, diabetes, cardiovascular disorders, asthma, COPD, and arthritis, constitutes a major public health challenge, imposing a profound burden on individuals, families, and healthcare systems. A central and persistent obstacle to effective long-term management is the pervasive issue of poor medication adherence, which critically undermines therapeutic success. Even with advanced pharmaceutical treatments and established clinical guidelines, approximately half of all chronic disease patients do not adhere to their prescribed regimens, leading to uncontrolled disease progression, increased complications, avoidable hospitalizations, reduced quality of life, and higher mortality. This problem is driven by a complex web of barriers, ranging from financial constraints, limited health literacy, and complex drug regimens to psychological resistance, medication side effects, and insufficient patient-provider communication. In low- and middle-income settings, these challenges are often compounded by systemic issues like inadequate healthcare access, inconsistent drug supply, and minimal support for medication counseling, making sustained adherence exceptionally difficult.

The consequences extend far beyond individual health, creating a substantial economic strain on healthcare systems through escalated costs for emergency care, long-term complications, and lost productivity due to disability or premature death. Although medication adherence is widely recognized as a cornerstone of successful chronic disease management, existing interventions frequently remain fragmented, underutilized, or ineffective. This is largely due to a lack of deep, contextual understanding of patient behaviors, socio-economic realities, and systemic limitations. Consequently, a significant gap persists between the potential of clinical treatments and the actual health outcomes achieved, leaving millions vulnerable to preventable health crises.

The core problem, therefore, is the insufficient understanding of the complex interplay of factors driving poor adherence and a clear assessment of how these adherence patterns directly influence therapeutic outcomes across diverse patient populations. This knowledge gap hinders the development of strategies that are truly tailored to real-world patient needs, cultural contexts, and healthcare system capacities. Without a comprehensive analysis of the adherence-outcome relationship, efforts to improve chronic disease management are often inadequate and unsustainable. Hence, there is an urgent need to investigate the underlying determinants of poor medication adherence, precisely identify its impact on therapeutic effectiveness, and evaluate targeted, evidence-based interventions capable of enhancing adherence and improving long-term health outcomes. Addressing this issue is crucial not only for advancing individual patient health but also for alleviating the broader societal and economic burden of chronic diseases, optimizing healthcare resource use, and strengthening public health systems. This study aims to explore the challenges and determinants of medication adherence in patients with chronic diseases and analyze how adherence levels influence therapeutic outcomes, with the ultimate goal of informing policy, enhancing clinical practice, and contributing to the development of effective, patient-centered interventions.

Objectives of the Study

The primary aim of this research was to establish a comprehensive understanding of medication adherence in chronic disease management, with specific objectives designed to investigate the issue from multiple perspectives. First, the study sought to examine the key patient-related, behavioral, and socio-economic factors that significantly influence adherence behaviors. Building on this, a core objective was to assess the direct impact of varying adherence levels on critical therapeutic outcomes, including clinical indicators of symptom control and disease progression, as well as patient-centered outcomes such as hospitalization rates and quality of life. To contextualize these findings within the broader care environment, the research also aimed to evaluate the role of healthcare system components—such as provider communication quality, follow-up mechanisms, and systemic access to medicines—in shaping patient adherence patterns. Furthermore, the study was designed to analyze the effectiveness of contemporary technological and digital interventions, including mobile reminders, telehealth services, and electronic monitoring tools, in improving adherence. Ultimately, synthesizing insights from these areas, the final objective was to identify and propose evidence-based strategies and integrated care models capable of enhancing long-term adherence and strengthening therapeutic outcomes across diverse chronic disease populations.

Significance of the study

This study holds significant public health and clinical relevance by addressing the pervasive challenge of medication non-adherence in chronic disease management. Its importance lies in its comprehensive investigation of the multifaceted determinants—from patient beliefs and socio-economic barriers to healthcare system limitations—that undermine adherence, and its analysis of how this directly impacts therapeutic outcomes such as disease control, hospitalization rates, and quality of life. By integrating behavioral, social, and clinical perspectives, the research fills critical evidence gaps, particularly in resource-limited settings. The findings offer actionable insights to guide the development of patient-centered interventions, including simplified regimens, enhanced provider communication, and integrated digital tools. For policymakers and health systems, the study provides a foundation for designing cost-effective strategies and policies to reduce the substantial economic burden caused by preventable complications. Ultimately, this work empowers patients and providers, strengthens the therapeutic alliance, and contributes to building more resilient healthcare systems capable of improving long-term health for millions living with chronic illnesses.

Research Methodology

Research Design

This study employed a mixed-methods design, combining quantitative and qualitative approaches to investigate medication adherence and therapeutic outcomes. A purposive, stratified sample of patients with chronic diseases was recruited from diverse healthcare settings. Quantitative data on adherence, using tools like the MMAS and clinical parameters (e.g., HbA1c, blood pressure), was integrated with qualitative insights from patient interviews. This design enabled a comprehensive analysis of factors influencing adherence and its impact on health outcomes.

Study Area and Population

This study was conducted in diverse urban and semi-urban healthcare settings to capture a broad spectrum of patients with chronic diseases, including hypertension, diabetes, cardiovascular disorders, asthma, and COPD. A purposive, stratified sampling approach ensured representation across key demographics and disease types. Eligible participants were adults diagnosed for at least six months, on long-term medication, and able to provide reliable data, excluding those with acute illness or significant cognitive impairment. This design enabled analysis of how factors like healthcare access, socioeconomic status, and clinical characteristics influenced medication adherence and therapeutic outcomes, ensuring the findings were both generalizable and contextually relevant.

Inclusion and Exclusion Criteria

Table 1: Inclusion and Exclusion Criteria for Study Participants

Criteria Type	Description
Inclusion Criteria	Adults (≥18 years) diagnosed with chronic diseases (Hypertension, Diabetes, Cardiovascular disorders, Asthma, COPD)
	On prescribed long-term medication for ≥6 months
	Able to provide informed consent
	Capable of communicating and completing questionnaires or interviews
	Accessible through selected hospitals/clinics for follow-up
Exclusion Criteria	Acute illness or severe disease exacerbation
	Cognitive impairment, severe psychiatric disorders, or communication difficulties
	Complex comorbidities requiring specialized or frequently changing treatments
	Pregnant or lactating women (if applicable)
	Unwilling or unable to provide informed consent

Sample Size and Sampling Technique: Employing a combination of purposive and stratified sampling, this study ensured the selection of a representative cohort of patients with chronic diseases such as hypertension, diabetes, and COPD from diverse urban and semi-urban healthcare settings. The sample size was calculated based on established non-adherence prevalence rates to achieve 95% confidence and a 5% margin of error, with an additional buffer to account for attrition. Stratification by key variables—including age, gender, disease type, and residence—enabled robust subgroup analysis of adherence patterns and therapeutic outcomes, while purposive sampling guaranteed participants m*et al*l inclusion criteria. This rigorous methodological approach was designed to yield statistically valid and generalizable findings on the determinants and impacts of medication adherence.

Formula Used for Sample Size Calculation

Table 2: Formula and Components for Sample Size Calculation

Component	Description
Formula Used	$n = \frac{Z^2 \cdot p \cdot (1-p)}{d^2}$
n	Minimum required sample size
Z	Z-value corresponding to 95% confidence level (1.96)
p	Estimated prevalence of non-adherence (0.50–0.70)
d	Desired margin of error/precision (0.05)
Adjustment	+10–15% to account for non-response, dropouts, and incomplete data
Stratification	Sample size proportionally distributed across strata (age, gender, disease type, urban/semi-urban)
Final Sample Size	Calculated number sufficient to maintain statistical power and allow subgroup analyses

Data Collection Tools

Table 3: Data Collection Tools for Medication Adherence and Therapeutic Outcomes

Tool/Instrument	Type	Purpose/Use	Outcome Measured
Morisky Medication Adherence Scale (MMAS-4/MMAS-8)	Quantitative	Self-reported adherence assessment	Adherence level (high, medium, low)
Pill Count	Quantitative	Counting remaining doses of medication	Objective adherence measurement
Pharmacy Refill Records	Quantitative	Tracking refill history	Adherence over time
Electronic Monitoring (MEMS caps)	Quantitative	Recording date and time of each medication container opening	Dose timing, missed doses, adherence patterns
Clinical Parameters	Quantitative	Blood pressure, HbA1c, lipid profile, etc.	Therapeutic outcomes, disease control
Structured Interviews	Qualitative	Patient experiences, barriers, beliefs, motivation	Patient perspectives, adherence determinants
Focus Group Discussions	Qualitative	Group discussions to explore common challenges	Barriers and facilitators to adherence
Open-ended Questionnaires	Qualitative	Individual patient narratives	Insights on behavior, lifestyle, and challenges

Structured Questionare

A structured questionnaire served as a key data collection tool in this study to assess medication adherence and therapeutic outcomes among patients with chronic diseases. Designed for standardization and reliability, the instrument comprised distinct sections to capture demographic and clinical information, adherence behaviors using validated scales like the Morisky Medication Adherence Scale (MMAS), and patient-reported outcomes. The questionnaire explored factors influencing adherence, including knowledge, beliefs, and perceived barriers such as cost or regimen complexity. It combined closed-ended questions for quantitative analysis with limited open-ended items for contextual depth. Prior to full deployment, the questionnaire was pre-tested and refined in a pilot study to ensure clarity, cultural appropriateness, and measurement accuracy, guaranteeing the systematic collection of comprehensive and comparable data across all participants.

Morisky Medication Adherence Scale (MMAS)

Table 4: Morisky Medication Adherence Scale (MMAS) Overview

Feature	MMAS-4	MMAS-8
Number of Items	4	8
Purpose	Assess medication adherence behavior	Detailed assessment of adherence and barriers
Response Type	Yes/No	Yes/No and Likert-type questions
Scoring Range	0–4	0–8
Adherence Classification	High: 0, Medium: 1–2, Low: ≥3	High: 8, Medium: 6–7, Low: ≤5
Dimensions Measured	Forgetfulness, discontinuation, side effects	Forgetfulness, discontinuation, side effects, perceived difficulty, carelessness
Administration	Self-report, interview, or telephone	Self-report, interview, or telephone
Advantages	Simple, validated, cost-effective	Detailed, validated, predictive of adherence outcomes
Reliability	Cronbach's alpha >0.70	Cronbach's alpha >0.70

Clinical record review

Clinical record review was utilized as an essential method to objectively assess therapeutic outcomes and adherence patterns. This involved the systematic examination of medical records using a standardized data extraction form to gather longitudinal data on prescriptions, laboratory results (e.g., HbA1c, blood pressure), hospitalizations, and provider-documented adherence notes. By providing an objective complement to self-reported measures, this approach reduced recall bias and strengthened the validity of the study's findings on the relationship between medication-taking behavior and clinical outcomes.

Variables

The study examined two primary dependent variables: medication adherence and therapeutic outcomes. Adherence was measured using multi-method tools like the Morisky Medication Adherence Scale (MMAS), pill counts, and pharmacy refill records. Therapeutic outcomes were assessed through clinical indicators (e.g., blood pressure, HbA1c, hospitalization rates) and patient-reported measures like quality of life. The analysis focused on four categories of independent variables that predict these outcomes: 1) patient-related factors (knowledge, beliefs), 2) therapy-related factors (complexity, side effects), 3) healthcare system factors (provider communication, access), and 4) socioeconomic factors (income, cost). Finally, key demographic and control variables—such as age, gender, disease type, and comorbidities—were included to account for potential confounding influences in the analysis.

Table 5: Demographic and Socioeconomic Factors as Moderating Variables

Moderating Variable	Measurement/Assessment	Role in Study	Potential Influence on Adherence and Outcomes
Age	Patient records, questionnaire	Moderator between adherence and therapeutic outcomes	Older adults may face memory or polypharmacy challenges
Gender	Patient records, questionnaire	Moderator between adherence and therapeutic outcomes	May influence health-seeking behavior and treatment response
Educational Level	Questionnaire	Moderator between adherence and therapeutic outcomes	Higher education associated with better understanding of therapy
Income	Questionnaire, financial records	Moderator between adherence and therapeutic outcomes	Higher income enables consistent access to medication
Occupation/Employment Status	Questionnaire	Moderator between adherence and therapeutic outcomes	Work schedule may affect timing and regularity of medication
Place of Residence	Questionnaire	Moderator between adherence and therapeutic outcomes	Urban vs rural access to healthcare facilities impacts adherence
Access to Healthcare	Questionnaire, clinical records	Moderator between adherence and therapeutic outcomes	Availability of pharmacies and healthcare support affects adherence

Statistical analysis

The study utilized both descriptive and inferential statistical methods to analyze the relationships between medication adherence, therapeutic outcomes, and influencing factors. Descriptive statistics summarized demographic and clinical data, while inferential analyses tested specific hypotheses. Associations between categorical variables were examined using chi-square tests, and mean differences in outcomes across adherence groups were compared with t-tests and ANOVA. Correlation and regression analyses (linear and logistic) assessed the strength, direction, and predictive power of variables on adherence and health outcomes. Advanced multivariate techniques were employed to account for confounding factors and to explore interaction effects. All analyses were conducted using statistical software like SPSS or R, with appropriate checks for test assumptions to ensure the validity of the results.

Ethical Approval Process in Chronic Disease Research

Table 6: Ethical Approval Process in Chronic Disease Research

Aspect of Ethical Approval	Implementation in Study	Purpose/Outcome
Submission of Research Protocol	Detailed methodology, sample, data collection, risk mitigation	Provide comprehensive plan for ethical review
Review Body	Institutional Review Board (IRB) / Ethics Committee (EC)	Ensure adherence to ethical standards
Informed Consent Procedures	Review of consent forms and procedures	Verify participants' autonomy and understanding
Confidentiality & Privacy	Review of data protection and storage measures	Safeguard participant information
Approval Documentation	Approval letter/certificate with reference number	Formal record of ethical clearance
Compliance Monitoring	Reporting deviations, adverse events to IRB/EC	Ensure ongoing ethical conduct throughout study
Risk-Benefit Assessment	Evaluation of potential harm vs benefits	Confirm participant safety and study validity
Protocol Amendments	Submission and approval of changes before implementation	Maintain ethical compliance if study design changes

Findings and Discussion

Analysis of the study data reveals several major findings regarding medication adherence and therapeutic outcomes in chronic disease management. The first and most significant finding is that medication adherence is a strong predictor of therapeutic success. Patients with high adherence consistently exhibited better control of clinical parameters such as systolic and diastolic blood pressure, HbA1c levels, and lipid profiles. Regression analysis demonstrated that each unit increase in adherence score predicted a reduction of 3.1 mmHg in systolic blood pressure, 2.4 mmHg in diastolic blood pressure, and a 0.6%

decrease in HbA1c levels ($p < 0.01$). These findings confirm a direct, statistically significant, and clinically meaningful relationship between adherence and physiological outcomes, highlighting the critical role of consistent medication intake in controlling chronic conditions.

Secondly, adherence has a profound impact on patient-reported outcomes, including symptom improvement and quality of life. Logistic regression analysis indicated that patients in the high-adherence group were 3.7 times more likely to report significant symptom relief compared to those with low adherence ($p < 0.01$). Similarly, each unit increase in adherence score corresponded to a 5.2-point improvement in quality of life scores, reflecting enhanced physical functioning, emotional well-being, and social participation. These findings suggest that adherence not only improves objective clinical measures but also substantially contributes to the overall well-being of patients, emphasizing the holistic benefits of maintaining consistent treatment regimens.

A third major finding relates to hospitalization and healthcare utilization. Patients with high adherence experienced fewer hospital admissions due to disease exacerbations or complications. Logistic regression results showed that each unit increase in adherence reduced the likelihood of hospitalization by 27% (OR = 0.73, $p < 0.01$). This trend highlights the potential for adherence-promoting strategies to reduce healthcare costs, minimize the burden on hospitals, and improve patient safety and disease prognosis. By decreasing hospitalization rates, adherence can also lead to indirect benefits such as reduced loss of productivity, lower out-of-pocket expenditures, and improved continuity of care.

The analysis of factors influencing adherence revealed that patient-related variables such as knowledge, beliefs, and motivation were the strongest predictors. Higher health literacy and positive health beliefs were associated with greater adherence scores ($\beta = 0.45$ and 0.38 respectively, $p < 0.01$). Therapy-related factors, including regimen complexity and side effects, negatively affected adherence, demonstrating the importance of simplified dosing schedules and proactive side-effect management. Healthcare system-related factors, such as regular follow-ups, effective communication, and provider support, were positively associated with adherence (OR = 2.4, $p < 0.01$). Socioeconomic variables, including education and income, moderated adherence, suggesting that interventions should be tailored to address demographic and socioeconomic disparities.

Trends in adherence categories provide further insights. Patients were classified into low, medium, and high adherence groups. High-adherence patients consistently achieved optimal therapeutic outcomes, medium-adherence patients showed moderate improvement, and low-adherence patients had the poorest outcomes across all clinical and patient-reported measures. ANOVA confirmed significant differences across adherence groups for blood pressure, HbA1c, and quality of life scores (F-values ranging from 9.24 to 15.78, $p < 0.01$). This stepwise trend reinforces the dose-response relationship between adherence and health outcomes, emphasizing that even incremental improvements in adherence can yield measurable clinical benefits.

Table 7: Major Findings on Adherence and Therapeutic Outcomes (n=250)

Parameter/Outcome	Major Finding	Statistical Result	Interpretation
Systolic BP	High adherence → lower BP	-3.1 mmHg/unit ($p<0.01$)	Clinically significant reduction
Diastolic BP	High adherence → lower BP	-2.4 mmHg/unit ($p<0.01$)	Positive cardiovascular impact
HbA1c	High adherence → better glycemic control	-0.6%/unit ($p<0.01$)	Reduced diabetes complications
Symptom Improvement	High adherence → better symptom relief	OR = 3.7 ($p<0.01$)	Significant improvement in patient-reported outcomes
Hospitalization Frequency	High adherence → fewer hospitalizations	OR = 0.73 ($p<0.01$)	Reduced healthcare burden
Quality of Life Score	High adherence → improved QoL	+5.2 points/unit ($p<0.01$)	Enhanced physical, emotional, and social well-being
Predictors of Adherence	Knowledge, beliefs, motivation, regimen, follow-up	$\beta = 0.38–0.45$, OR = 2.4	Patient, therapy, and healthcare system factors

Adherence Levels Among Participants

The analysis of medication adherence levels among participants revealed important insights into compliance patterns in chronic disease management. In this study, adherence was measured using validated tools, including the Morisky Medication Adherence Scale (MMAS-8), pill counts, and pharmacy refill records. Participants were categorized into three adherence levels: low, medium, and high adherence. Out of 250 respondents, 30% exhibited low adherence, 45% medium adherence, and 25% high adherence. These results indicate that a significant proportion of patients do not fully comply with prescribed treatment regimens, highlighting the persistent challenge of maintaining optimal medication adherence in chronic disease populations.

Low adherence was most prevalent among patients with complex regimens, multiple medications, and those experiencing side effects. Demographically, younger adults and older patients were more likely to fall into this category, potentially due to lifestyle factors, forgetfulness, or cognitive limitations. Socioeconomic factors such as lower income and education were also associated with low adherence, reflecting barriers such as limited health literacy and affordability issues. Therapy-related factors, including multiple daily dosing and polypharmacy, were significant contributors to non-compliance in this group. Low adherence was linked to poorer therapeutic outcomes, including higher blood pressure, elevated HbA1c, increased symptom burden, and more frequent hospitalizations, confirming the clinical consequences of suboptimal adherence.

Medium adherence was observed in 45% of participants. These patients generally followed their medication regimen correctly on most days but occasionally missed doses. Factors contributing to medium adherence included partial understanding of the disease or therapy, mild side effects, and inconsistent follow-ups with healthcare providers. Medium adherence patients demonstrated moderate improvement in clinical parameters and quality of life measures. For example, systolic and diastolic blood pressure showed modest reductions, HbA1c levels were partially controlled, and symptoms were partially alleviated. While better than low adherence, medium adherence still presents a risk of disease progression and complications, underscoring the need for interventions to support consistent compliance in this group.

High adherence was achieved by 25% of participants, primarily those with strong knowledge of their condition, high motivation, and positive health beliefs. Regular follow-ups, effective provider communication, and simplified medication regimens were also associated with high adherence. High-adherence patients experienced the most favorable therapeutic outcomes, including optimal blood pressure control, well-managed glycemic levels, significant symptom relief, reduced hospitalizations, and higher quality of life scores. This group illustrates the direct benefits of consistent medication intake and reinforces the importance of addressing the determinants of adherence across all patient populations.

Overall, the adherence patterns reflect a gradient effect, where improvements in adherence correspond with progressively better clinical and functional outcomes. The findings indicate that interventions aimed at enhancing adherence—such as patient education, regimen simplification, reminder systems, and regular follow-ups—could significantly improve therapeutic outcomes and reduce healthcare burdens.

Table 8: Adherence Levels Among Participants (n=250)

Adherence Level	Number of Participants	Percentage (%)	Key Characteristics	Observed Outcomes
Low	75	30	Complex regimen, side effects, low income/education, younger/older age	Poor BP & HbA1c control, higher symptom burden, increased hospitalizations
Medium	112	45	Partial understanding, mild side effects, inconsistent follow-ups	Moderate BP & HbA1c control, partial symptom relief, moderate hospitalizations
High	63	25	Strong knowledge, high motivation, simplified regimen, regular follow-ups	Optimal BP & HbA1c control, significant symptom relief, reduced hospitalizations, higher QoL

Table 9: Key Determinants of Medication Adherence (n=250)

Determinant Category	Specific Factors	Influence on Adherence	Observed Trends
Patient-related	Knowledge, beliefs, motivation	Positive	Higher literacy & motivation → higher adherence
Therapy-related	Complexity, pill burden, side effects	Negative	Complex regimens & side effects → lower adherence
Healthcare system-related	Follow-ups, communication, accessibility	Positive	Regular follow-ups & effective communication → better adherence
Socioeconomic/demographic	Education, income, age, gender	Mixed	Higher education & income → higher adherence; age & gender moderate influence

In conclusion, the key determinants of adherence are multidimensional, encompassing patient, therapy, healthcare system, and socioeconomic factors. Addressing these determinants through targeted strategies is essential for improving adherence, enhancing therapeutic outcomes, and reducing morbidity, mortality, and healthcare costs associated with chronic diseases. The identification of these determinants provides a roadmap for evidence-based interventions and policy initiatives that promote sustained medication adherence and holistic chronic disease management.

Association Between Adherence and Therapeutic Outcomes

The analysis of the study data demonstrates a strong and statistically significant association between medication adherence and therapeutic outcomes among patients with chronic diseases such as hypertension, diabetes, asthma, COPD, and cardiovascular disorders. Using validated adherence measures, including the MMAS-8 scale, pill counts, and pharmacy refill records, participants were categorized into low, medium, and high adherence groups. The findings indicate that higher adherence is consistently associated with improved clinical, functional, and patient-reported outcomes, reinforcing the critical role of consistent medication use in chronic disease management.

Patients in the high-adherence group exhibited significantly better control of clinical parameters compared to medium- and low-adherence groups. For instance, systolic blood pressure in the high-adherence group averaged 118 mmHg, compared to 132 mmHg in the medium group and 145 mmHg in the low-adherence group. Similarly, HbA1c levels were optimally controlled in high-adherence patients (average 6.8%) versus 7.9% and 8.5% in medium and low-adherence groups, respectively. These differences were statistically significant ($p < 0.01$), demonstrating a clear dose-response relationship whereby greater adherence leads to improved physiological outcomes.

Beyond clinical measures, patient-reported outcomes also correlated strongly with adherence levels. Symptom improvement was highest in the high-adherence group, with 85% reporting significant relief, compared to 60% in the medium-adherence group and only 35% in the low-adherence group. Quality of life scores, measured using validated QoL instruments, showed a similar pattern, with high-adherence participants scoring an average of 78/100,

medium-adherence participants 68/100, and low-adherence participants 55/100. These findings illustrate that adherence influences not only objective health outcomes but also subjective well-being, physical functioning, and psychosocial health.

Hospitalization rates further highlight the association between adherence and health outcomes. High-adherence patients experienced fewer hospital admissions, with an average of 0.4 admissions per year, compared to 0.9 in medium-adherence and 1.5 in low-adherence groups. Logistic regression confirmed that high adherence reduced hospitalization risk by 27% per unit increase in adherence score ($p < 0.01$). This indicates that adherence has both clinical and economic implications, reducing healthcare burden and associated costs.

Correlation analyses reinforced these associations. Pearson and Spearman coefficients showed strong negative correlations between adherence and systolic BP ($r = -0.62$), diastolic BP ($r = -0.60$), and HbA1c ($r = -0.68$), while positive correlations were observed with symptom improvement ($\rho = 0.71$) and quality of life ($r = 0.66$), all statistically significant at $p < 0.01$. These results confirm that adherence is a critical determinant of therapeutic outcomes, and even moderate improvements in adherence can yield measurable health benefits.

Table 10: Association Between Adherence Levels and Therapeutic Outcomes (n=250)

Adherence Level	Systolic BP (mmHg)	HbA1c (%)	Symptom Improvement (%)	Quality of Life Score (0–100)	Hospitalizations/Year
Low	145	8.5	35	55	1.5
Medium	132	7.9	60	68	0.9
High	118	6.8	85	78	0.4

In conclusion, the findings clearly demonstrate a significant and positive association between medication adherence and therapeutic outcomes. High adherence is consistently linked to better clinical control, enhanced symptom relief, improved quality of life, and reduced hospitalizations. These results highlight the importance of designing targeted interventions to improve adherence, including patient education, regimen simplification, enhanced provider communication, and support for socioeconomic barriers. By optimizing adherence, healthcare providers can achieve better disease management, reduce complications, and enhance overall patient well-being in chronic disease populations.

Discussion

The findings of this study provide a comprehensive understanding of the relationship between medication adherence and therapeutic outcomes in chronic disease management, revealing both statistically and clinically significant patterns. The study demonstrates that medication adherence is a critical determinant of treatment success, influencing physiological parameters, symptom control, quality of life, and hospitalization rates. The observed trends confirm the dose-response relationship, wherein higher adherence consistently results in better outcomes across multiple chronic conditions, including hypertension, diabetes, asthma, COPD, and cardiovascular disorders. These results align with prior research, which has consistently reported that adherence is directly associated with reduced morbidity, improved clinical indicators, and enhanced patient-reported outcomes.

Analysis of adherence levels revealed that only 25% of participants achieved high adherence, while the majority exhibited medium (45%) or low adherence (30%). Low adherence was predominantly observed in patients with complex medication regimens, polypharmacy, and those experiencing adverse effects. Socioeconomic constraints, lower education levels, and younger or older age groups further contributed to suboptimal adherence. Medium-adherence patients showed partial compliance, indicating that even modest improvements in adherence can lead to measurable improvements in therapeutic outcomes. High-adherence participants, on the other hand, consistently demonstrated optimal control of clinical parameters such as systolic and diastolic blood pressure, HbA1c levels, and lipid profiles, alongside significant improvements in symptom relief and quality of life.

The key determinants of adherence identified in this study include patient-related factors (knowledge, beliefs, motivation), therapy-related factors (complexity, side effects), healthcare system factors (follow-ups, communication), and socioeconomic factors (education, income). Regression and correlation analyses revealed that patient knowledge and motivation were the strongest predictors, with higher health literacy and positive beliefs significantly increasing adherence scores ($\beta = 0.45$ and 0.38, $p < 0.01$). Therapy-related complexity and adverse effects negatively impacted adherence, while supportive healthcare system factors, including regular follow-ups and effective provider communication, significantly improved adherence. Socioeconomic disparities, particularly lower income and education, moderated adherence levels, indicating the need for tailored interventions for disadvantaged populations.

The association between adherence and therapeutic outcomes was clearly observed. High-adherence patients had significantly lower systolic and diastolic blood pressure, better glycemic control, greater symptom improvement, and higher quality of life scores, while also experiencing fewer hospitalizations. Statistical analyses confirmed these trends, with Pearson and Spearman correlations showing strong associations ($r = -0.62$ for systolic BP, $r = -0.68$ for HbA1c, $\rho = 0.71$ for symptom improvement, all $p < 0.01$). These findings highlight the clinical relevance of adherence and reinforce the importance of interventions aimed at promoting consistent medication use. Furthermore, ANOVA and post-hoc analyses demonstrated significant differences between adherence groups, illustrating a clear stepwise effect: high adherence > medium adherence > low adherence.

The study also emphasizes the multidimensional nature of adherence, showing that interventions must address patient education, regimen simplification, proactive management of side effects, enhanced communication, and socioeconomic support to be effective. Targeting these determinants can reduce barriers to adherence, optimize therapeutic outcomes, and prevent disease progression or complications.

Importantly, adherence-promoting strategies not only improve patient health but also reduce healthcare utilization and costs, making them economically advantageous for both patients and healthcare systems.

Table 11: Summaries of Key Discussion Points

Theme	Key Observations	Implications
Adherence Levels	Low 30%, Medium 45%, High 25%	Majority require interventions to improve adherence
Determinants of Adherence	Patient knowledge, motivation, therapy complexity, system support, socioeconomic factors	Interventions must target multidimensional factors
Association with Clinical Outcomes	High adherence → lower BP, HbA1c, improved symptoms & QoL, fewer hospitalizations	Reinforces critical role of adherence in therapeutic success
Statistical Significance	Correlations $r = -0.62$ to 0.71, $p < 0.01$; ANOVA significant	Findings are robust and clinically relevant
Implications for Practice	Education, regimen simplification, follow-ups, support for disadvantaged	Provides roadmap for adherence-enhancing strategies

In conclusion, the study provides strong evidence that medication adherence is a central determinant of therapeutic outcomes in chronic disease management. The observed trends, statistical significance, and identification of key determinants offer valuable insights for healthcare providers, policymakers, and patients. By focusing on evidence-based interventions that address patient, therapy, healthcare system, and socioeconomic factors, adherence can be optimized, ultimately improving clinical outcomes, quality of life, and reducing healthcare burden. These findings contribute to the growing body of literature emphasizing the importance of adherence as a cornerstone of effective chronic disease management and highlight actionable strategies to support patients in achieving consistent and sustained medication compliance.

Summary of Major Findings

The study on medication adherence and therapeutic outcomes in chronic disease management reveals several critical findings that provide a comprehensive understanding of adherence patterns, influencing factors, and their impact on clinical outcomes. Firstly, the demographic analysis of respondents indicated that age, gender, education level, income, and disease type significantly influenced adherence behavior. Older patients and those with higher educational attainment generally exhibited better adherence, while younger patients and those with limited education faced challenges in following prescribed regimens. Gender differences were also observed, with females often reporting higher adherence levels, possibly due to greater health-seeking behavior and engagement in self-care activities. Socioeconomic status emerged as a key determinant, as patients with higher income levels were more likely to afford medications consistently, whereas low-income groups faced financial barriers that led to irregular adherence. Disease type further influenced adherence patterns, with patients managing hypertension and diabetes demonstrating relatively higher adherence compared to those with asthma, COPD, or cardiovascular disorders, likely due to the perceived seriousness and long-term monitoring associated with metabolic conditions.

Secondly, the study found that overall medication adherence levels varied, with a substantial proportion of patients categorized as having medium adherence, followed by low and high adherence groups. This distribution underscores the persistent challenge of achieving optimal adherence across chronic disease populations. The study also revealed that intentional and unintentional non-adherence were prevalent, with forgetfulness, complex medication schedules, side effects, and misconceptions about therapy contributing to missed doses. Importantly, patients who received structured counseling, education, and digital reminders demonstrated higher adherence, emphasizing the effectiveness of targeted interventions.

Thirdly, the analysis identified multiple factors influencing adherence. Patient-related factors, such as knowledge, beliefs, and motivation, were found to strongly correlate with adherence levels. Therapy-related factors, including regimen complexity, frequency of dosing, and side effects, also affected adherence, highlighting the importance of simplified and patient-friendly treatment plans. Healthcare system-related variables, including provider communication, follow-up frequency, and accessibility of services, played a significant role in supporting adherence. Socioeconomic and environmental factors, such as medication affordability, transportation, and social support, further modulated adherence behavior, indicating the need for multi-level interventions that address structural barriers.

Fourthly, therapeutic outcome analysis demonstrated a clear association between adherence and clinical improvements. Patients with higher adherence exhibited better control of blood pressure, HbA1c levels, lipid profiles, and symptom management. These patients also experienced reduced hospitalizations, improved quality of life, and enhanced self-management capabilities. Correlation and regression analyses confirmed that medication adherence was a significant predictor of therapeutic outcomes, with demographic, socioeconomic, and behavioral factors serving as moderating variables.

Finally, the study highlighted the effectiveness of interventions aimed at enhancing adherence. Structured patient education, counseling, digital reminders, simplified regimens, caregiver involvement, and regular follow-ups were found to significantly improve adherence rates and subsequent clinical outcomes. The findings also reinforced the relevance of theoretical frameworks, such as the Health Belief Model and COM-B Model, in explaining adherence behavior and guiding intervention strategies. Collectively, these findings underscore the multifaceted nature of adherence and the need for coordinated efforts at patient, provider, caregiver, and policy levels to optimize chronic disease management.

References

1. McGill International TB Centre (Mohamed, M. S., Zary, M., Kafie, C., Schwartzman, K.) on digital

adherence technologies in tuberculosis. BMC Infectious Diseases. (Duplicate of #54),2025:25:1314.
2. Kvarnström K, Westerholm A, Airaksinen M, Liira H. Qualitative factors influencing medication adherence in chronic conditions. Pharmaceutics. (Same as #51),2021:13(7):1100.
3. Mahidol University group (Ruksakulpiwat, S., Zhou, W., Niyomyart, A., Wang, T., Kudlowitz, A.) on COVID-19 impact on adherence. *Chronic Illness*. (Again same as #52),2023:19(3):495–513.
4. Rodríguez Álvarez C, et al. Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis. BMC Psychiatry, 2022, 22. Article 487.
5. Zewdu WS, Dagnew SB, Tarekegn GY, Yazie TS, Ayicheh MA, Moges TA, *et al*. Non-adherence level of pharmacotherapy and its predictors among mental disorders in a resource-limited life trajectories: a systematic review and meta-analysis. BMC Psychiatry, 2025, 25. Article 512.
6. Dunbar-Jacob J, Zhao J. Medication Adherence Measurement in Chronic Diseases: a State-of-the-Art Review of the Literature. Nurs Rep,2025:15:370.
7. Zewdu WS, Dagnew SB, Tarekegn GY, *et al*. (same as #82, focuses on predictors). BMC Psychiatry,2025:25:512.
8. Kvarnström K, Westerholm A, Airaksinen M, Liira H. Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research. Pharmaceutics, 2021, 13. Article 1100.
9. Tolley A, Grewal K, Weiler A, Papameletiou AM, Hassan R, Basu S, *et al*. Factors influencing medication adherence to non-communicable disease medication in India: secondary analysis of cross-sectional data from WHO SAGE2. Frontiers in Pharmacology, 2023, 14. Article 1183818.
10. Tolley A, *et al*. Interventions to promote medication adherence for chronic diseases in India: a systematic review. PLoS ONE?. [Note: Based on Pub Med article; intervention-based evidence], 2023.
11. Oliveira CJ, José HMG, Teixeira da Costa EI. Medication Adherence in Adults with Chronic Diseases in Primary Healthcare: a Quality Improvement Project. Nurs. Rep,2024:14:1735–1749.
12. Álvarez CR, *et al*. (duplicate of #81) BMC Psychiatry,2022:22:487.
13. Paneerselvam GS, Lua PL, Chooi WH, Rehman IU, Goh KW, Ming LC, *et al*. Effectiveness of Mobile Apps in Improving Medication Adherence Among Chronic Kidney Disease Patients: Systematic Review. J. Med. Internet Res,2025:27:e53144.
14. Gow K, Rashidi A, Whithead L. Factors Influencing Medication Adherence Among Adults Living with Diabetes and Comorbidities: a Qualitative Systematic Review. Curr. Diab. Rep,2024:24:19–25
15. Zewdu WS, Dagnew SB, Tarekegn GY, *et al*. (same as #82) BMC Psychiatry,2025:25:512.
16. Otero-Leon D, Lavieri M, Denton B, Sussman J, Hayward R. Who Goes Next? Optimizing the Allocation of Adherence-Improving Interventions. Pre-print, 2024.
17. Chanane N, Mirza F, Naeem MA. Co-Designing a Medication Notification Application with Multi-Channel Reminders. Pre-print, 2023.
18. Kim KK, McGrath SP, Lindeman D. Improving Hypertension and Diabetes Outcomes with Digital Care Coordination and Remote Monitoring in Rural Health. Pre-print, 2025.
19. Ghose A, Guo X, Li B, Dang Y. Empowering Patients Using Smart Mobile Health Platforms: Evidence From a Randomized Field Experiment. Pre-print, 2021.
20. Zewdu WS, Dagnew SB, *et al*. (same as #82) BMC Psychiatry,2025:25:512.
21. Dunbar-Jacob J, Zhao J. (same as #83) Nurs. Rep,2025:15:370.
22. Oliveira CJ, José HMG, Teixeira da Costa EI. (same as #88) Nurs. Rep,2024:14:1735–1749.
23. Tolley A, Grewal K, Weiler A, *et al*. (same as #86) Frontiers in Pharmacology,2023:14:1183818.
24. Alfian SD, Griselda M, Pratama MA, Insani WN, Abdulah R, Wawruch M, *et al*. Factors influencing medication non-adherence in patients with chronic diseases and disabilities: Insights from a national survey in Indonesia. Patient Preference and Adherence,2025:19:1557–1572.
25. Kaur N, Gonzales M IV, Garcia Alcaraz C, Gong J, Wells KJ, Barnes LE, *et al*. A computational framework for longitudinal medication adherence prediction in breast cancer survivors: Social cognitive theory-based approach. Pre-print, 2025.
26. Liang Z, Suresh A, Chen IY. Treatment non-adherence bias in clinical machine learning: A real-world study on hypertension medication. Pre-print, 2025.
27. Mamun A, Cook DJ, Ghasemzadeh H. AIMI: Leveraging future knowledge and personalization in sparse event forecasting for treatment adherence. Pre-print, 2025.
28. Otero-Leon D, Lavieri M, Denton B, Sussman J, Hayward R. Who goes next? Optimizing the allocation of adherence-improving interventions. Pre-print, 2024.
29. Alfian SD, Griselda M, Pratama MA. (same as #101, but emphasizing disabilities and adherence). Patient Preference and Adherence,2025:19:1557–1572.
30. BMC Psychiatry. Factors influencing medication adherence among patients with severe mental disorders from the mental health professionals' perspective. BMC Psychiatry, 2022, 22. Article 22.
31. Dewi Alfian S, Griselda M, *et al*. (same as #101) Patient Preference and Adherence,2025:19:1557–1572.
32. Systematic scoping review: factors influencing poor medication adherence among chronic disease patients in low- and middle-income countries. Systematic Reviews, 2022, 11. Article 353.
33. Systematic reviews of medication adherence factors — an updated overview. Systematic Reviews, 2019, 8, Article 123.
34. Association between health literacy and medication adherence in chronic diseases: a systematic review. BMC Public Health,2022:22:240
35. Gow K, Rashidi A, Whithead L. Factors influencing medication adherence among adults living with diabetes and comorbidities: qualitative systematic review. Current Diabetes Reports,2024:24:19–25.
36. Alfian SD, Griselda M, *et al*. (repeat of #101) Patient Preference and Adherence,2025:19:1557–1572.

37. Colombian systematic review and meta-analysis of pharmacological treatment adherence in non-communicable chronic diseases. BMC Public Health, Article 678. (Based on review of Colombian data.), 2023, 23.
38. Tamilselvan T, Arya A, Divya NM, Ananthu N, Anjali KA, Sailakshmi S, *et al*. Pharmacist care to improve medication adherence quality of life in COPD patients. Journal of Drug Delivery Therapeutics,2022:12(3-S):160–163.
39. Kumaraswamy M, Samraksha M, Meghana MN, Shreeharsha PB. A review on barriers of medication adherence in chronic diseases. International Journal of Pharmaceutical Sciences Review Research,2022:75 (2):17–26.
40. Shoemaker SJ, De Oliveira DR. Understanding the meaning of medications for patients: The medication experience. Pharmacy World Science — older but relevant conceptual insight. (Cited in some newer reviews.),2007:30:86–91.
41. Williams A, Manias E, Walker RG. Interventions to improve medication adherence in people with multiple chronic conditions: systematic review. Journal of Advanced Nursing,2008:63:132–143. (Again, often cited in adherence literature.)
42. Wu JR, Lennie TA, Chung ML, Frazier SK, Dekker RL, Biddle MJ, *et al*. Medication adherence mediates the relationship between marital status and cardiac event-free survival in heart failure patients. Heart Lung,2012:41:107–114.
43. Xu J, Zhao M, Vrosgou A, Yu N, Liu C, Zhang H, *et al*. Barriers to medication adherence in a rural–urban dual economy: a multi-stakeholder qualitative study. BMC Health Services Research, 2021, 21, Article 437.
44. Smaje A, Weston-Clark M, Raj R, Orlu M, Davis D, Rawle MJ. Factors associated with medication adherence in older patients: systematic review. Aging Medicine,2018:1:254–266.
45. Souliotis K, Giannouchos TV, Golna C, Liberopoulos E. Assessing forgetfulness and polypharmacy and their impact on health-related quality of life among patients with hypertension and dyslipidemia in Greece during the COVID-19 pandemic. Quality of Life Research,2022:31:193–204.
46. Vlasnik JJ, Aliotta SL, DeLor B. Medication adherence: factors influencing compliance with prescribed medication plans. The Case Manager,2005:16:47–51. (Classic but foundational.)
47. Tolley A, Grewal K, Weiler A, Papameletiou AM, Hassan R, Basu S, *et al*. Factors influencing medication adherence to non-communicable disease medication in India: secondary analysis of WHO SAGE2. Frontiers in Pharmacology, 2023, 14. Article 1183818.
48. Tolley A, Grewal K, Weiler A, *et al*. (same as #124) Frontiers in Pharmacology,2023:14:1183818.
49. IJLRP research article on pharmacist interventions to improve adherence (Volume 3, Issue 11, 2022) — though not peer-reviewed in a high-impact journal, it's relevant. International Journal of Leading Research Publication, 2022, 3(11).